Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine

Eur Respir J. 2016 Nov;48(5):1527-1529. doi: 10.1183/13993003.01552-2016.

Marina Tadolini^{1

2}, Rangjung Dolma Lingtsang^{3

2}, Simon Tiberi^{4

2}, Martin Enwerem^{5

2}, Lia D'Ambrosio^{6

7

2}, Tsetan Dorji Sadutshang³, Rosella Centis⁶, Giovanni Battista Migliori⁸

¹ Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
² These authors contributed equally.
³ Delek Hospital, Dharamshala, India.
⁴ Division of Infection, Barts Health NHS Trust, London, UK.
⁵ Amity Health Consortium, Johannesburg, South Africa.
⁶ Fondazione S. Maugeri, IRCCS, Care and Research Institute, Tradate, Italy.
⁷ Public Health Consulting Group, Lugano, Switzerland.
⁸ Fondazione S. Maugeri, IRCCS, Care and Research Institute, Tradate, Italy [email protected].

No abstract available

Publication types